ABSTRACT A double-blind, cross-over study was designed to evaluate the effects of L-carnitine in patients with peripheral vascular disease. After drug washout, 20 patients were randomly assigned to receive placebo or L-carnitine (2 g bid, orally) for a period of 3 weeks and were then crossed over to the other treatment for an additional 3 weeks. The effect on walking distance at the end of each treatment period was measured by treadmill test. Absolute walking distance rose from 174 + 63 m with placebo to 306 122 m (p < .01) with carnitine. Biopsy of the ischemic muscle, carried out before and after 15 days of L-carnitine administration in four additional patients, showed that treatment significantly increased total carnitine levels. An additional goal of this study was to ascertain the elfects of L-carnitine on the metabolic changes induced by exercise in the affected limb. In six patients under control conditions, arterial and popliteal venous lactate and pyruvate concentrations were determined at rest, when the maximal walking distance was reached, and 5 min after the walking test. Twenty-four hours later, L-carnitine was administered intravenously (3 g as a bolus followed by an infusion of 2 mg/kg/min for 30 min) and metabolic assessments were repeated. Five minutes after the walking test, popliteal venous lactate concentration increased by 107 + 16% before treatment and by only 54 + 32% (p < .01) after carnitine. Furthermore, carnitine induced a more rapid recovery to the resting value of the lactate/pyruvate ratio. These data suggest that carnitine improves pyruvate utilization and oxidative phosphorylation efficiency in the skeletal muscle of the ischemic leg. L-Carnitine, administered intravenously to 18 patients at the same dosage as above, did not modify blood flow or the ankle/arm systolic blood pressure ratio. In an additional eight patients, this intravenous dose produced an increase in walking distance similar to that observed with oral treatment. In conclusion, this study demonstrates that L-carnitine, although not affecting the general or regional hemodynamics, improves the walking capacity of patients with intermittent claudication, probably through a metabolic mechanism. Circulation 77, No. 4, 767-773, 1988. THE MOST IMPORTANT problem in the treatment of obstructive vascular disease is to make the energy supply adequate to the metabolic demand in the hypoxic area. In peripheral vascular disease, this goal is sought only by interventions aimed at increasing blood flow to the ischemic muscle. Many reports on ischemic heart-disease, however, suggest that a metabolic agent such as carnitine (3-hydroxy-4N-trimethylaminobutyrate) may protect the ischemic myocardium' and improve the stress tolerance of the heart2-4 by increasFrom the
ing the availability of substrates required for energy production. A decrease in myocardial free L-carnitine content has been observed in experimental animals as a result of acute5' 6 and chronic7 myocardial ischemia. Similarly, a decrease in free carnitine concentration has been demonstrated in the skeletal muscle during exercise. 8 Therefore, we designed this study to evaluate whether L-carnitine may enhance the walking ability of patients with intermittent claudication by interfering with the metabolic events taking place in the ischemic skeletal muscle.
Patients and methods BREVETTI et al.
informed consent before participation. All of them had been affected by peripheral arterial insufficiency at the second stage of Fontaine's classification (i.e., claudication on effort without pain at rest and/or trophic lesions in the affected leg) for at least 1 year before enrollment in the study. The diagnosis was established in advance on the basis of history, physical examination, impedance plethysmography, and decrease in the ankle/arm systolic blood pressure ratio after exercise. Patients with heart failure, coronary artery disease, and severe hypertension were excluded from the study. At the time of the first visit, all of the patients were treated with one or more of the following drugs: flunarizine, papaverine, pentoxifylline, and raubasine. A pretrial drug washout period of 2 weeks was allowed in all cases. During the entire period of the study, diuretics and oral hypoglycemic agents were the only drugs allowed. All tests were carried out in the morning after an overnight fast in a quiet room at the constant temperature of 21 + 10 C. All patients were on a low-fat, low-cholesterol diet; diabetics were also on a standard low-carbohydrate diet ( Clinical assessment. Two double-blind, cross-over studies were carried out to assess the ability of L-carnitine to improve walking distance when given orally for long-term or intravenously for short-term treatment. To ensure that the patient admitted to the double-blind treatment phase of the study had a stable AWD, three treadmill tests were conducted on all patients during the second week of the washout period, and only those exhibiting a change in AWD of 20% or more were included in this protocol.
The effect of the oral treatment was assessed in 20 male patients aged 40 to 69 years (mean 59.8 + 7.0) who fulfilled all the inclusion criteria. Patients entered the first drug treatment phase, in which they were randomly assigned to receive placebo or L-carnitine (2 g bid, orally). Placebo and carnitine tablets were identical in size, shape, and color. After 3 weeks, each patient crossed over to the other drug, and treatment was continued for an additional 3 weeks. At the end of each treatment period, at 9 A.M., before the mnorning dose, blood flow and ankle/brachial systolic blood pressure ratio were measured in the affected limb at rest. Patients then performed a treadmill test, during which arterial blood pressure and the electrocardiogram were monitored continuously and AWD was assessed. The evaluation of subjective symptoms such as coldness, paresthesias, tiredness, and pain during walking was a secondary aim of this study. The intensity of each symptom was scored on a six-point scale: -3 = total relief, -2 = marked improvement, -1 = slight improvement, 0 = no change, 1 = slight deterioration, 2 = marked deterioration.
The effect of short-term intravenous administration of Lcarnitine was assessed in an additional eight patients who were randomly assigned to placebo or L-carnitine 3 g iv as a bolus followed by continuous infusion of 2 mg/kg/min for 30 min. After showed an increase in AWD from the washout value of 147.0 + 67 to 288.0 ± 97 m (p < .01); when they crossed to placebo, AWD returned to a value similar to figure  2 , in the absence of carnitine the popliteal venous 770 lactate/pyruvate (L/P) ratio increased from 21.9 ± 6 to 40.2 ± 14 (p < .05) during exercise, and 5 min after exercise L/P was still higher than at rest (31.6 ± 13); p < .01). After carnitine, the L/P ratio during exercise increased from 21.7 ± 13 to 30.0 ± 15 (p < .01) and returned to the rest value during the recovery period (20.1 ± 8). Throughout the study, L/P ratios were similar in the treated and in the control groups. Furthermore, arterial lactate and pyruvate concentration and L/P ratios were similar in treated and untreated patients at rest, during exercise, and after recovery (table 4).
Muscle carnitine assay. Table 5 shows changes in total, free, and esterified carnitine concentrations induced by L-carnitine in patients with peripheral vascular disease.
Normal values were obtained from six normal subjects matched to the patients with peripheral arterial disease with respect to age and sex, chosen from a group of 46 normal individuals previously studied in our laboratory.
Before treatment, total carnitine in the biopsied muscle was 19.3 ± 3.6 nmol/mg noncollagen protein, a value not different from that found in normal muscle.
After treatment, total carnitine increased in all subjects to a level as high as 24.6 ± 2.9 nmol/mg noncollagen TABLE 4 protein (p < .05), thus demonstrating a direct uptake of the administered L-carnitine by the biopsied muscle. The observed increase in total carnitine is accounted for by an increase in both free carnitine and short-chain acylcarnitine. On the contrary, the concentration of long-chain acylcarnitine decreased, although not significantly, after L-carnitine supplementation. It must be noted that free and total carnitine values before treatment are within the normal range.
Discussion
The pharmacologic treatment of intermittent claudication still represents a challenge. Vasodilators are the most used drugs in the therapy of chronic obstructive vascular disease, although their efficacy is far from being proved.6' 17 Much more effective seem to be drugs capable of reducing blood viscosity. Among these, pentoxifylline has been demonstrated to increase walking distance18' 19 as a result of increased blood flow and enhanced tissue oxygenation in the affected limb.7' 21 Other reports, however, failed to demonstrate any objective benefit.22 Our study describes a new approach to the treatment of peripheral vascular disease. We have shown that L-carnitine, although not affecting general or regional hemodynamics, improves the walking ability of patients with intermittent claudication, probably through a metabolic mechanism.
Carnitine has been found to protect ischemic myocardium in animals1 and to improve the stress tolerance in patients with coronary artery disease. 2 CoA/CoA ratio would explain the above-mentioned stimulation of pyruvate dehydrogenase. In our short-term exercise protocol, the preferentially utilized substrate was conceivably muscle glycogen or blood glucose.27 As a consequence, a large increase of pyruvate production should be expected. The stimulation of pyruvate dehydrogenase activity by the increased availability of carnitine might explain both the decreased production of lactate and the higher yield of energy, resulting from pyruvate oxidation. It is well known that glucose utilization in anaerobic glycolysis yields 2 ATP, whereas its utilization in the aerobic pathway produces 36 ATP. This enhancement of pyruvate oxidation, hence in energy production, may result in an improvement of walking ability after treatment with L-carnitine.
An additional mechanism by which treatment with carnitine might be beneficial is the removal of longchain acyl-CoA.28 An accumulation of these metabolites in oxygen-deficient conditions may be detrimental to the cellular membrane stability. An of long-chain fatty acid utilization by supplemented L-carnitine seems to be ruled out by the observation that in muscles of the affected leg even before L-carnitine, the concentration of total carnitine is above the value considered rate-limiting for the optimal fatty acid oxidation.29 Therapeutic implications. The results of this study suggest that carnitine may allow ischemic skeletal muscle to reach a higher level of energy expenditure before claudication develops. Therefore L-carnitine may represent an effective agent for treating peripheral vascular disease. Furthermore, because the mechanism of action of this factor differs from that of other available therapeutic agents, a combination of more traditional drugs with carnitine may be regarded as a useful means for treating this disease.
